Featured Research

from universities, journals, and other organizations

A Candidate Biomarker To Improve Treatment Of Lupus Patients

Date:
May 8, 2005
Source:
John Wiley & Sons, Inc.
Summary:
A recent study provides the basis for a new laboratory biomarker to better evaluate new therapies as well as to help doctors more effectively treat lupus patients at risk for serious complications.

Study associates high expression of interferon induced genes with increased disease severity, including kidney disease

Related Articles


A chronic disease of the immune system, systemic lupus erythematosus (SLE) affects approximately 1.5 million people nationwide, according to the Lupus Foundation of America. Characterized by the production of autoantibodies throughout the body, SLE affects women more than men and can cause problems ranging from skin rash and joint pain to kidney failure and stroke. The wide range of disease symptoms among patients can make SLE difficult to diagnose and treat, especially since current laboratory tests or biomarkers have limitations.

A recent study provides the basis for a new laboratory biomarker to better evaluate new therapies as well as to help doctors more effectively treat lupus patients at risk for serious complications. Published in the May 2005 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), the findings shed important light on the role of interferon, a protein critical to immunity released into the bloodstream, in the progression of SLE.

Supported by the Alliance for Lupus Research, the Lupus Research Institute, the Mary Kirkland Center for Lupus Research, and the NIH, the study was conducted by a team of researchers with the Kirkland Center, Hospital for Special Surgery, and Weill Medical College of Cornell University in New York City. Led by Kyriakos A. Kirou, M.D. and Mary K. Crow, M.D., the team set out to test the hypothesis that activation of a particular interferon pathway-- the type I interferon pathway--is more common among SLE patients with the highest disease activity. Activation of this pathway is indicated by high levels of expression of interferon-inducible genes (IFIGs) in peripheral blood mononuclear cells.

The team collected blood samples from 77 SLE patients, 22 disease controls (20 with rheumatoid arthritis and 2 with autoimmune uveitis), and 28 healthy controls. Drs. Kirou and Crow and their associates made an effort to match SLE patients with both control groups with regard to sex--with women as the majority--and race, with progressively decreasing ratios of whites, African-Americans, Asians, and Hispanics. In addition, the SLE patients and disease controls were well matched for age, disease duration, and daily prednisone dose. The team also gathered relevant clinical data on the SLE patients. Then, they analyzed and compared all the blood samples for levels of IFIG expression. Overall, SLE patients scored higher than the other disease patients, as well as the healthy donors, for activation of the type I interferon pathway. Among SLE patients, the highest scoring group was strongly associated with increased disease severity, increased disease activity, and certain autoantibodies known to react with proteins that bind to the important nucleic acid, RNA. SLE patients with high scores were also more likely to suffer from kidney disease.

"Our data have defined a subgroup of SLE patients who have more severe disease, with frequent kidney involvement, and more active disease, as measured by complement activation, suggesting that determination of IFIG expression may prove a useful approach to selection of patients for clinical studies," states Dr. Kirou. "Our next challenge will be to plan clinical studies to validate the measurement of IFIG as a biomarker for active lupus." Beyond its clinical applications, this study provides new clues to the underlying mechanisms that drive autoimmunity.

###

Article: "Activation of the Interferon-alpha Pathway Identifies a Subgroup of Systemic Lupus Erythematosus Patients With Distinct Serologic Features and Active Disease," Kyriakos A. Kirou, Christina Lee, Sandhya George, Kyriakos Louca, Margaret G.E. Peterson, and Mary K. Crow, Arthritis & Rheumatism, May 2005; 52:5; pp. 1491-1503.


Story Source:

The above story is based on materials provided by John Wiley & Sons, Inc.. Note: Materials may be edited for content and length.


Cite This Page:

John Wiley & Sons, Inc.. "A Candidate Biomarker To Improve Treatment Of Lupus Patients." ScienceDaily. ScienceDaily, 8 May 2005. <www.sciencedaily.com/releases/2005/05/050507183346.htm>.
John Wiley & Sons, Inc.. (2005, May 8). A Candidate Biomarker To Improve Treatment Of Lupus Patients. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2005/05/050507183346.htm
John Wiley & Sons, Inc.. "A Candidate Biomarker To Improve Treatment Of Lupus Patients." ScienceDaily. www.sciencedaily.com/releases/2005/05/050507183346.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins